SecBot SecBot

PRRUF

IMMUTEP Ltd
OTC· Pharmaceutical Preparations· Inc. C3· CIK 0001506184 Biotech & Drug Discovery
$0.0200 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $0.0200
1 year
−90.0%
from $0.2000 · Oct 27
30 days
−33.3%
from $0.0300
52-week range
$0.0200–0.3200
−94% from high · low Oct 19
Avg volume 20D
1.1K
Oct 22 spike 20.0K
Short interest
15.33M
+0.3%
Filing reports
2
analyzed by SecBot
SecBot read BEARISH 2 reports · latest
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest BEARISH Immutep reported discontinuation of its lead TACTI-004 Phase III trial for eftilagimod alfa in first-line…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest +0.3% to 15.33M shares.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $0.0200 on Oct 23.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 1, 2026 SEC
Immutep reported discontinuation of its lead TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small…
6-K — Impact 8/10
Apr 1, 2026 SEC
Howard Russell J, an insider at IMMUTEP Ltd, filed a Form 3 disclosing beneficial ownership of 1,717,977 ordinary…
3 — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Apr 22, 2026
Clinical Trial
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Phase 2 · COMPLETED

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$4.0M
Next FY———$3.0M

Short side

FINRA· Sep 30, 2026
15,326,768
shares short
+0.3%
vs prior settlement

SecBot reports

2 filings · 0 bullish · 1 bearish · 1 neutral
All PRRUF filing & press-release reports (2)